Born J, Jann K, Assmann K J, Lindahl U, Berden J H
Division of Nephrology, University Hospital St. Radboud, 6500 HB Nijmegen, The Netherlands.
J Biol Chem. 1996 Sep 13;271(37):22802-9. doi: 10.1074/jbc.271.37.22802.
The Escherichia coli K5 capsular polysaccharide has the same (GlcUA-->GlcNAc)n structure as the nonsulfated heparan sulfate/heparin precursor polysaccharide. A monoclonal antibody (mAb 865) against the K5 polysaccharide has been described (Peters, H., Jürs, M., Jann, B., Jann, K., Timmis, K. N., and Bitter-Sauermann, D. (1985) Infect. Immun. 50, 459-466). In this report, we demonstrate the binding of anti-K5 mAb 865 to N-acetylated sequences in heparan sulfates and heparan sulfate proteoglycans but not to heparin. This is shown by direct binding and fluid phase inhibition of mAb 865 in an enzyme-linked immunosorbent assay. In this system we found that the binding of the mAb decreased with increasing sulfate content of the polysaccharide. By testing chemically modified K5 and heparin polysaccharides, we found that each of the modifications that occur during heparan sulfate (HS) synthesis (N-sulfation, C-5 epimerization, and O-sulfation) prevents recognition by mAb 865. Samples of heparan sulfate from human aorta (HS-II) were selectively degraded so as to allow the separate isolation of N-sulfated and N-acetylated block structures. N-Sulfated oligosaccharides (obtained after N-deacetylation by hydrazinolysis followed by nitrous acid deamination at pH 3.9) were not recognized by mAb 865, in contrast to N-acetylated oligosaccharides (obtained after nitrous acid deamination at pH 1.5), although the reactivity was lower than for intact HS-II. Analysis of the latter's pH 1.5 deamination products by gel filtration indicated that a minimal size of 18 saccharide units was necessary for antibody binding. These results lead us to propose bivalent antibody-heparan sulfate interaction, in which both F(ab) domains of the mAb interact with their epitopes, both of which are present in a single large (>/=18 saccharide units) N-acetylated domain and additionally with single epitopes present in two N-acetylated sequences (each <18 saccharide units) bridged by a short N-sulfated domain. Immunohistochemistry with mAb 865 on cryostat sections of normal human kidney tissue, revealed its binding to most but not all renal basement membranes. However, all renal basement membranes contain heparan sulfate, as shown by a mAb against heparitinase-digested heparan sulfate stubs (mAb 3G10). This finding indicates that not all heparan sulfate chains present in basement membranes express the mAb 865 epitopes. Besides the normal distribution, mAb 865 staining was found in fibrotic and sclerotic lesions in vessels, interstitium, and mesangium in transplant kidneys with chronic vascular rejection. Occasionally, a decrease of staining was observed within tubulo-interstitium and glomeruli. These findings show that N-acetylated sequences in heparan sulfates can be demonstrated by anti-K5 mAb 865 in normal and diseased kidneys.
大肠杆菌K5荚膜多糖具有与非硫酸化硫酸乙酰肝素/肝素前体多糖相同的(GlcUA→GlcNAc)n结构。一种针对K5多糖的单克隆抗体(单克隆抗体865)已被报道(彼得斯,H.,尤尔斯,M.,扬,B.,扬,K.,蒂米斯,K. N.,以及比特 - 绍尔曼,D.(1985年)《感染与免疫》50,459 - 466)。在本报告中,我们证明了抗K5单克隆抗体865与硫酸乙酰肝素和硫酸乙酰肝素蛋白聚糖中的N - 乙酰化序列结合,但不与肝素结合。这通过酶联免疫吸附测定中该单克隆抗体865的直接结合和液相抑制得以证明。在该系统中,我们发现单克隆抗体的结合随着多糖硫酸含量的增加而降低。通过测试化学修饰的K5和肝素多糖,我们发现硫酸乙酰肝素(HS)合成过程中发生的每种修饰(N - 硫酸化、C - 5差向异构化和O - 硫酸化)都能阻止单克隆抗体865的识别。对来自人主动脉的硫酸乙酰肝素(HS - II)样本进行选择性降解,以便分别分离出N - 硫酸化和N - 乙酰化的嵌段结构。与N - 乙酰化寡糖(在pH 1.5下经亚硝酸脱氨后获得)相比,N - 硫酸化寡糖(在肼解脱乙酰化后,接着在pH 3.9下进行亚硝酸脱氨获得)不被单克隆抗体865识别,尽管其反应性低于完整的HS - II。通过凝胶过滤对后者pH 1.5脱氨产物的分析表明,抗体结合所需的最小糖单位大小为18个。这些结果使我们提出二价抗体 - 硫酸乙酰肝素相互作用,其中单克隆抗体的两个F(ab)结构域与其表位相互作用,这两个表位都存在于单个大的(≥18个糖单位)N - 乙酰化结构域中,并且还与由短的N - 硫酸化结构域桥接的两个N - 乙酰化序列(每个<18个糖单位)中存在的单个表位相互作用。用单克隆抗体865对正常人肾组织冰冻切片进行免疫组织化学分析,发现其与大多数但并非所有肾基底膜结合。然而,如针对肝素酶消化的硫酸乙酰肝素残端的单克隆抗体(单克隆抗体3G10)所示,所有肾基底膜都含有硫酸乙酰肝素。这一发现表明,基底膜中并非所有的硫酸乙酰肝素链都表达单克隆抗体865表位。除了正常分布外,在患有慢性血管排斥的移植肾的血管、间质和系膜的纤维化和硬化病变中发现了单克隆抗体865染色。偶尔,在肾小管间质和肾小球内观察到染色减少。这些发现表明,硫酸乙酰肝素中的N - 乙酰化序列可通过抗K5单克隆抗体865在正常和患病肾脏中得以证实。